[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565523":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":34,"responsibleParty":90,"collaborators":93,"id":103,"slug":18,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":111,"maxAge":18,"enrollmentInfo":112,"targetDuration":18,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Erasmus Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Participants receive access to the Digizorg Melanoma app, on top of care as usual.",[13],"Device: Digizorg Melanoma app",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Participants have access to care as usual, but have no access to the Digizorg Melanoma app and its functionalities.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","Digizorg Melanoma app","The Digizorg Melanoma app is a digital survivorship care plan, in which ellaborated information regarding diagnosis, treatment and follow-up and supportive care, adjusted to one's personal preferences and disease characteristics, is offered in the form of a mobile application.",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Marjolein Lugtenberg, PhD","CONTACT","+31614448940","m.lugtenberg@erasmusmc.nl",{"name":32,"role":28,"phone":18,"phoneExt":18,"email":33},"June Kievits, MD","j.kievits@erasmusmc.nl",[35,54,67,79],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Albert Schweitzer hospital","RECRUITING","Dordrecht","South Holland","3318 AT","Netherlands",{"type":43,"coordinates":44},"Point",[45,46],4.67361,51.81,{"lat":46,"lon":45},[49,52],{"name":50,"role":28,"phone":18,"phoneExt":18,"email":51},"Peter Plaisier, PhD","p.w.plaisier@asz.nl",{"name":50,"role":53,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":55,"status":37,"city":56,"state":39,"zip":57,"country":41,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Erasmus MC","Rotterdam","3015GD",{"type":43,"coordinates":59},[60,61],4.47917,51.9225,{"lat":61,"lon":60},[64,66],{"name":27,"role":28,"phone":65,"phoneExt":18,"email":30},"+316 144488940",{"name":27,"role":53,"phone":18,"phoneExt":18,"email":18},{"facility":68,"status":69,"city":56,"state":39,"zip":70,"country":41,"cosmosGeoPoint":71,"geoPoint":73,"contacts":74},"Franciscus Gasthuis & Vlietland hospital","NOT_YET_RECRUITING","3045 PM",{"type":43,"coordinates":72},[60,61],{"lat":61,"lon":60},[75,78],{"name":76,"role":28,"phone":18,"phoneExt":18,"email":77},"Frederique Beverdam, PhD","f.beverdam@franciscus.nl",{"name":76,"role":53,"phone":18,"phoneExt":18,"email":18},{"facility":80,"status":37,"city":56,"state":39,"zip":81,"country":41,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Maasstad hospital","3079 DZ",{"type":43,"coordinates":83},[60,61],{"lat":61,"lon":60},[86,89],{"name":87,"role":28,"phone":18,"phoneExt":18,"email":88},"Kai Munte, MD","munteK@maasstadziekenhuis.nl",{"name":87,"role":53,"phone":18,"phoneExt":18,"email":18},{"type":53,"investigatorFullName":91,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Marjolein Lugtenberg","Doctor",[94,97,99,101],{"name":95,"class":96},"BeterKeten","UNKNOWN",{"name":98,"class":6},"Albert Schweitzer Hospital",{"name":100,"class":6},"Maasstad Hospital",{"name":102,"class":6},"Franciscus Gasthuis","100565523",false,"NCT06643286","Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma","Personalised Survivorship Care for Patients With Melanoma: A Multicenter Randomised Controlled Trial of the Survivorship Care Plan App","Melanoma SCP","Inclusion Criteria:\n\n* 18 years or older\n* Patients who have received a primary diagnosis of cutaneous melanoma stage I to II in the past 0-4 months\n\nExclusion Criteria:\n\n* Patients with irresectable stage III melanoma, patients receiving neo-adjuvant treatment and patients with stage IV melanoma.\n* Patients who do not have (sufficient) command of the Dutch language.","ALL","18 Years",{"count":113,"type":114},180,"ESTIMATED","INTERVENTIONAL",[117],"NA","A multicentre randomised controlled trial (RCT) will be conducted to evaluate the effectiveness of the digital personalised Melanoma Survivorship Care Plan (SCP) app. A total of hundred-eighty melanoma patients (stage I and II) will be randomised to receive either the SCP Melanoma app or usual care. The app provides survivors with personalized healthcare information on diagnosis, treatment and follow-up and supportive care, tailored to their melanoma stage and phase and information needs.Through questionnaires, medical file records, patient-reported outcomes and use of medical care will be evaluated. In addition, log-data, questionnaires and interviews will be used to evaluate the process of the uptake and implementation of the digital SCP.",[120,121,122,123],"Melanoma (Skin)","Melanoma, Stage II, Stage I","Melanoma Stage","Survivorship",[125,126,127],"Survivorship care","Application","RCT","2025-06-06",{"date":130,"type":131},"2025-06-11","ACTUAL",{"date":133,"type":131},"2025-04-01",{"date":135,"type":114},"2026-12-01",{"name":5,"class":6},4]